Transgene Biotek Ltd
Incorporated in 1990, Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.[1]
- Market Cap ₹ 57.2 Cr.
- Current Price ₹ 7.55
- High / Low ₹ 12.5 / 2.45
- Stock P/E
- Book Value ₹ -0.86
- Dividend Yield 0.00 %
- ROCE -57.6 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
26.24 | 15.01 | 0.97 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.20 | |
25.06 | 15.78 | 2.79 | 1.81 | 1.32 | 2.84 | 5.12 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.77 | |
Operating Profit | 1.18 | -0.77 | -1.82 | -1.51 | -1.14 | -2.56 | -5.00 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.57 |
OPM % | 4.50% | -5.13% | -187.63% | -503.33% | -633.33% | -914.29% | -4,166.67% | -971.43% | -311.76% | -511.11% | -1,033.33% | -285.00% | |
17.07 | 0.00 | -114.37 | 0.01 | 0.17 | 0.66 | 10.27 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.16 | |
Interest | 0.62 | 0.20 | 0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 |
Depreciation | 0.38 | 1.02 | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 1.30 |
Profit before tax | 17.25 | -1.99 | -133.41 | -19.04 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -1.85 |
Tax % | 32.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
11.65 | -1.99 | -133.40 | -19.04 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -1.85 | |
EPS in Rs | 1.77 | -0.30 | -17.61 | -2.51 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.25 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -42% |
5 Years: | -13% |
3 Years: | % |
TTM: | 33% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 6% |
3 Years: | 13% |
TTM: | 74% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 10% |
3 Years: | 16% |
1 Year: | 206% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 65.77 | 65.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
Reserves | 245.18 | 256.27 | 121.41 | 102.38 | 78.89 | -34.48 | -40.92 | -49.71 | -60.67 | -71.11 | -75.97 | -81.98 |
20.76 | 22.46 | 13.06 | 14.34 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.02 | 13.12 | |
34.02 | 24.14 | 139.21 | 137.84 | 123.15 | 30.88 | 31.97 | 31.45 | 31.43 | 31.01 | 25.40 | 25.57 | |
Total Liabilities | 365.73 | 368.64 | 349.45 | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 |
106.82 | 197.80 | 180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | |
CWIP | 0.23 | 0.29 | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 |
Investments | 0.00 | 92.20 | 92.20 | 92.20 | 92.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.11 |
258.68 | 78.35 | 76.38 | 74.44 | 59.65 | 24.98 | 23.82 | 23.68 | 23.79 | 23.80 | 23.84 | 24.05 | |
Total Assets | 365.73 | 368.64 | 349.45 | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
25.34 | 99.62 | -2.11 | -0.95 | 0.02 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | |
-144.15 | -101.06 | 1.46 | -0.02 | -0.02 | 0.00 | 3.05 | 1.74 | 0.00 | -0.04 | -0.10 | -0.01 | |
82.72 | 1.50 | 0.60 | 0.94 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | -36.09 | 0.06 | -0.05 | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.02 | 0.00 | -0.01 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 394.77 | 448.16 | 6,867.27 | 19,941.17 | 3,305.28 | 13.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Days | 12.92 | 6.40 | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | ||||
Days Payable | 441.40 | 437.74 | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | ||||
Cash Conversion Cycle | -33.72 | 16.82 | -19,002.11 | 19,941.17 | 3,305.28 | 13.04 | -4,653.75 | -3,163.33 | -1,338.33 | 0.00 | -1,042.86 | |
Working Capital Days | 1,167.75 | 53.01 | 692.37 | 1,533.00 | 2,331.94 | -1,733.75 | -21,413.33 | -35,717.86 | -14,277.94 | -4,785.56 | -7,908.33 | |
ROCE % | 6.44% | -0.51% | -6.58% | -9.27% | -11.85% | -17.10% | -14.75% | -25.79% | -34.93% | -49.11% | -73.14% | -57.55% |
Documents
Announcements
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Expertise:[1]
Company is in production and oral formulation of different proteins using TrabiORAL technology
a) Oncology[2]
b) Auto Immunity[3]
c) Drug Delivery[4]
d) Biogenerics[5]